From: UAB Comprehensive Diabetes Center <diabetescomm@reach.uab.edu>
Sent: Tuesday, November 12, 2024 10:01 AM

Subject: UCDC November/December Newsletter

Web Version

COMPREHENSIVE DIABETES CENTER
The University of Alabama at Birmingham

UCDC Newsletter: November/December 2024

The UAB Comprehensive Diabetes Center's Diabetes (UCDC) newsletter shares research, center, and member updates.

Could an osteoporosis drug treat Type 1 diabetes?

The UAB Comprehensive Diabetes Center is joining a phase 1/2 clinical trial of the FDA-approved drug denosumab to test its ability to improve beta cell function and blood sugar control in adults diagnosed with Type 1 diabetes in the past one to five years.

UCDC hosted congressional visit

Congressman Gary Palmer (AL-06) toured the UAB Comprehensive Diabetes Center on Wednesday, September 4, to learn more about the state of diabetes in Alabama.

Basu and colleagues find adolescents with T1D have higher insulin sensitivity than adults with T1D

Dr. Ananda Basu and colleagues recently assessed the difference in post-prandial glucose turnover between adolescents and adults with T1D by conducting a Triple Tracer Meal Study.

Bril and researchers shine light on relationship between insulin resistance and MASLD

After assessing 204 participants, Dr. Fernando Bril and researchers found that insulin resistance was a fundamental feature of MASLD whether the individual had a PNPLA3 gene variant, or not.

Shalev gives invited presentation on TXNIP at the Levine-Riggs Symposium



Dr. Anath Shalev was invited by conference organizers to present in Pasadena, CA, and was honored at symposium dinner.

Podcast: The role of telehealth in revolutionizing diabetes care

Dr. Anish Patel discusses how telehealth reduces hospitalizations and readmissions, while enabling more personalized treatment plans.

Get to know UCDC Researcher Justin Alexander



Justin Alexander is Lab Manager and Researcher in Dr. Sushant Bhatnagar's lab: "It is a fulfilling experience being a lab manager and making a difference within the center."

IN THE NEWS

Ramanadham with Diabetes Journal

"Selective Reduction of Ca^{2+}-Independent Phospholipase $A_2\beta$ ($iPLA_2\beta$)-Derived Lipid Signaling from Macrophages Mitigates Type 1 Diabetes Development"

EVENTS

Diabetes Plenary Lecture - Bogan

Thursday, Nov. 21

Noon

LRC/SHPB 224

Endocrinology Grand Rounds - Bouvet

Thursday, Dec. 5

Shalev with Frontiers

"A novel class of oral, non-immunosuppressive, beta cell-targeting, TXNIP-inhibiting T1D drugs is emerging"

Ramanadham with Frontiers

"Differential lipid signaling from $CD4^+$ and $CD8^+$ T cells contributes to type 1 diabetes development"

Noon

FOT 1101

Core and Shared Resource Day 2025

Tuesday, Jan. 7

West Pavilion Atrium

UAB Comprehensive Diabetes Center | News | Research

Want to be featured in our next newsletter?

Submit your news to diabetescomm@uabmc.edu.